Gujarat Kidney And Super Speciality Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a good return on equity (ROE) track record: 3 Years ROE 76.5%
- Company has a healthy return on capital (ROCE) of 32.3%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.32x)
- Working capital cycle has improved - days down from 190 to 1
- Company comfortably covers its interest (20.8x coverage)
- Company generates healthy free cash flow
CONS
- Total debt has risen sharply - up 99.6% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | 8850.00 | 60.90 | 127249.42 | 0.23 | 610.40 | 38.41 | 7043.50 | 20.56 | 21.73 | 15.70 |
| MAXHEALTH | 1037.20 | 69.29 | 100951.74 | 0.19 | 322.96 | 4.87 | 2366.17 | 16.70 | 14.97 | 25.29 |
| MANIPALHOS | 716.15 | 105.57 | 94200.74 | 0.00 | 2434.30 | — | 30906.30 | — | 13.93 | 23.83 |
| FORTIS | 887.30 | 63.93 | 66987.44 | 0.11 | 272.80 | 2.26 | 2545.03 | 17.46 | 14.07 | 21.28 |
| ASTERDM | 762.95 | 208.69 | 66504.25 | 0.39 | 29.28 | -68.70 | 1310.68 | 21.60 | 11.26 | 19.53 |
| MEDANTA | 1447.55 | 69.98 | 38920.53 | 0.03 | 157.25 | -1.09 | 1304.05 | 26.50 | 19.38 | 21.99 |
| NH | 1867.35 | 46.76 | 38161.31 | 0.24 | 207.27 | 5.37 | 2683.63 | 78.05 | 16.20 | 17.43 |
| KIMS | 768.85 | 158.06 | 32292.20 | 0.00 | 37.40 | -56.00 | 1179.50 | 35.33 | 11.51 | 19.03 |
| LALPATHLAB | 1909.40 | 59.14 | 32049.05 | 1.07 | 1705.00 | 1172.39 | 7977.00 | 1090.95 | 29.56 | 31.03 |
| AGARWALEYE | 507.00 | 108.33 | 16073.23 | 0.00 | 55.02 | 44.56 | 614.02 | 25.97 | 16.14 | 27.75 |
| VIJAYA | 1502.30 | 82.53 | 15473.35 | 0.13 | 53.10 | 37.61 | 230.98 | 22.83 | 30.28 | 42.66 |
| GKSL | 170.80 | 85.04 | 1346.64 | 0.00 | 53.21 | 884.82 | 342.89 | 2146.99 | 63.02 | 24.43 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| 9 | 12 | 10 | 15 | 13 | 23 | 31 | 34 | |
| 5 | 7 | 7 | 8 | 8 | 16 | 24 | 28 | |
| Operating Profit | 5 | 5 | 3 | 7 | 5 | 7 | 6 | 6 |
| OPM % | 51.65% | 38.93% | 26.69% | 49.02% | 39.60% | 29.68% | 20.60% | 18.30% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Profit before Tax | 4 | 4 | 2 | 7 | 4 | 5 | 5 | 7 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.85% | 28.54% | 26.24% | -2.99% | 23.58% |
| Net Profit | 0 | 0 | 0 | 5 | 3 | 4 | 5 | 5 |
| 0.65 | 0.52 | 0.25 | 0.85 | 0.52 | 0.52 | 0.81 | 0.66 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 0 | 0 | 5 | 40 | 101 | |
| 0 | 0 | 3 | 24 | 76 | |
| Operating Profit | -0 | -0 | 2 | 17 | 25 |
| OPM % | — | — | 40.86% | 41.12% | 24.34% |
| 1 | 0 | 1 | 0 | 2 | |
| Interest | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 1 | 0 | 0 | 3 | 5 |
| Profit before Tax | 0 | -0 | 2 | 13 | 21 |
| Tax % | 26.85% | -0.00% | 24.44% | 25.58% | 19.18% |
| Net Profit | 0 | -0 | 2 | 9 | 17 |
| EPS | 0.03 | -0.06 | 85.70 | 1.66 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 355%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 76%
- Last Year:
- 69%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 0 | 0 | 0 | 11 |
| Minority Interest | 0 | 0 | 0 | 1 |
| 0 | 0 | 2 | 15 | |
| 0 | 0 | 5 | 7 | |
| Trade Payables | 3 | 3 | 2 | 3 |
| -0 | -0 | 11 | 17 | |
| Total Liabilities | 4 | 4 | 20 | 55 |
| 3 | 0 | 14 | 31 | |
| 0 | 0 | 0 | 1 | |
| 0 | 0 | 4 | 15 | |
| Cash & Bank | 0 | 0 | 1 | 3 |
| 1 | 4 | 1 | 5 | |
| Total Assets | 4 | 4 | 20 | 55 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0 | 0 | 1 | 14 | |
| Cash from Investing | 0 | 0 | 0 | -18 |
| Cash from Financing | 0 | 0 | -0 | 6 |
| 0 | 0 | 1 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-04 - Gujarat Kidney And Super Speciality Limited has informed the Exchange about Copy of Newspaper Publication about mailing Annual report
2026-09-03 - Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026
2026-09-01 - Gujarat Kidney And Super Speciality Limited has informed the Exchange about Pre advertisement for Notice of 7th AGM
2026-08-27 - Gujarat Kidney And Super Speciality Limited has informed the Exchange about Schedule of meet
2026-08-24 - Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding Outcome of Board Meeting held on August 24, 2026.
2026-08-24 - Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding 'Outcome of Board Meeting' - Appointment of Additional Director subject to confirmation by shareholders at the ensuing Annual General Meeting and taking note of resolution passed by Postal ballot
2026-08-24 - Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding Appointment of Mrs Disha Bharpoda as Non- Executive Independent Director of the company w.e.f. August 24, 2026.
2026-08-14 - Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding 'Financial results for Quarter ended June 2026'.
2026-08-14 - Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
News
Recent coverage and analyst commentary for GKSL
Loading news…
AI Stock Analyst
Gujarat Kidney And Super Speciality Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account